EGFR and gastric cancer: Somatic single-nucleotide variants as drug candidates included variants of ARID1A, PI3KCA, SMARCA4, EGFR, and BAP. Until now, only drugs targeting ERBB2 and VEGF have been approved for the treatment of patients with metastatic GC, and the results have been unsatisfactory.